Apoptotic Regulation in Primitive Hematopoietic Precursors
Open Access
- 15 September 1998
- journal article
- Published by American Society of Hematology in Blood
- Vol. 92 (6), 2041-2052
- https://doi.org/10.1182/blood.v92.6.2041
Abstract
Bcl-2 and bcl-xL function as suppressors of programmed cell death. The expression of bcl-2 protein in vivo is associated with long-lived hematopoietic cells such as mature lymphocytes and early myeloid progenitors. Bcl-xL, a homologue of bcl-2, is also expressed in lymphocytes and thymocytes. In contrast, the bcl-2-related proteins (bax, bad, and bak) act by promoting apoptotic cell death as shown from their expression in hematopoietic cell lines. We analyzed the expression of bcl-2 and bcl-x proteins in hematopoietic precursors obtained from various cell sources in adult mobilized peripheral blood collected from 13 patients with solid tumors, 8 adult bone marrow, and 12 umbilical cord blood. The analysis was based on the expression of the proliferation and activation specific antigens, CD38 and class II (HLA-DR). Similarly, we analyzed the expression of bcl-2-related proteins bcl-xL, bax, bad, and bak before and during ex-vivo expansion. Hematopoietic precursors expressing strongly the CD34 antigen (CD34s+) and lacking CD38 or HLA-DR expression were analyzed by using three-color immunofluorescence staining. The majority of CD34+ cells expressed bcl-2 and unexpectedly showed a bimodal distribution of low and high expression. More cells that lacked or expressed low density CD38 expressed low bcl-2 than the more differentiated counterparts (those with high density CD38). Immaturity (ie, little or no HLA-DR) is associated with the expression of low bcl-2 compared with HLA-DR+. However, HLA-DR−/low population contained a lower number of cells expressing low bcl-2 (30% to 40%) than CD38−/low in comparable samples. The hematopoietic precursors with bcl-2low and bcl-2high formed a homogeneous population of undifferentiated lymphoid-like cells having a similar forward scatter. These cells expressed strongly the bcl-xL protein (>95%) but were bax low (4% to 12%), bad low (0% to 0.8%), and bak low (0% to 3%). The expression of apoptosis specific protein (ASP) was also low (3.4% ± 3.1%) as was Annexin V. In addition, the CD34+/CD38−showed low cell cycle activity (L and that the low bcl-2 expression did not promote apoptosis. During day 10 of ex vivo expansion of CD34+cells in liquid culture containing stem cell factor, interleukin-3 (IL-3), IL-6, IL-1β, and erythropoietin, the CD34+/CD38− cells expressed high bcl-2 as a single population histogram, and greater than 90% were bcl-xL high. However, the expression of pro- and apoptotic antigens increased: bax (10% to 15%), bad (5% to 8%), bak (6% to 14%), and ASP (6% to 10%). These results show the importance of monitoring the expression of these proteins when defining the culture conditions for ex vivo expansion. © 1998 by The American Society of Hematology.Keywords
This publication has 50 references indexed in Scilit:
- G‐CSF‐mobilized CD34+ peripheral blood stem cells are significantly less apoptotic than unstimulated peripheral blood CD34+ cells: role of G‐CSF as survival factorBritish Journal of Haematology, 1997
- Apoptosis in the Pathogenesis and Treatment of DiseaseScience, 1995
- Interleukin 7-dependent B lymphocyte precursor cells are ultrasensitive to apoptosis.The Journal of Experimental Medicine, 1994
- Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell deathCell, 1993
- bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell deathCell, 1993
- ApoptosisImmunology Today, 1993
- bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytesCell, 1991
- Programmed cell death: Apoptosis and oncogenesisCell, 1991
- Human hematopoietic precursors in long-term culture: single CD34+ cells that lack detectable T cell, B cell, and myeloid cell antigens produce multiple colony-forming cells when cultured with marrow stromal cells.The Journal of Experimental Medicine, 1990
- Life span of multipotential hematopoietic stem cells in vivo.The Journal of Experimental Medicine, 1990